Results 11 to 20 of about 10,433 (192)

Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model‐Informed Dosing Recommendations for Anticancer Drugs [PDF]

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Isavuconazole is a broad‐spectrum triazole approved for the treatment of invasive aspergillosis or mucormycosis in adults and children aged ≥ 1 year. Current prescribing information lacks guidance regarding the co‐administration of isavuconazole with anticancer drugs–limited by the availability of clinical drug–drug interaction (DDI) data in ...
Theunis C. Goosen, Xiaofeng Wu, Jian Lin, N. Cheruvu, Susan Raber, María Henriqueta Figueiredo, Manthena V. S. Varma   +6 more
openalex   +2 more sources

Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction

CPT: Pharmacometrics & Systems Pharmacology, 2022
Physiologically‐based pharmacokinetic (PBPK) models have an important role in drug discovery/development and decision making in regulatory submissions.
Luna Prieto Garcia, Anna Lundahl, Christine Ahlström, Anna Vildhede, Hans Lennernäs, Erik Sjögren   +5 more
doaj   +1 more source

Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans

Pharmaceutics, 2023
Enavogliflozin is a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor approved for clinical use in South Korea. As SGLT2 inhibitors are a treatment option for patients with diabetes, enavogliflozin is expected to be prescribed in various ...
Min-Soo Kim, Yoo-Kyung Song, Ji-Soo Choi, Hye Young Ji, Eunsuk Yang, Joon Seok Park, Hyung Sik Kim, Min-Joo Kim, In-Kyung Cho, Suk-Jae Chung, Yoon-Jee Chae, Kyeong-Ryoon Lee   +11 more
doaj   +1 more source

Prediction for optimal dosage of pazopanib under various clinical situations using physiologically based pharmacokinetic modeling

Frontiers in Pharmacology, 2022
This study aimed to apply a physiologically based pharmacokinetic (PBPK) model to predict optimal dosing regimens of pazopanib (PAZ) for safe and effective administration when co-administered with CYP3A4 inhibitors, acid-reducing agents, food, and ...
Chunnuan Wu, Chunnuan Wu, Chunnuan Wu, Bole Li, Bole Li, Bole Li, Shuai Meng, Shuai Meng, Shuai Meng, Linghui Qie, Linghui Qie, Linghui Qie, Jie Zhang, Jie Zhang, Jie Zhang, Guopeng Wang, Cong Cong Ren   +16 more
doaj   +1 more source

Agent-based modeling: a systematic assessment of use cases and requirements for enhancing pharmaceutical research and development productivity. [PDF]

, 2013
A crisis continues to brew within the pharmaceutical research and development (R&D) enterprise: productivity continues declining as costs rise, despite ongoing, often dramatic scientific and technical advances. To reverse this trend, we offer various
Hunt, C. Anthony, Hunt, CA, Kennedy, RC, Kim, SHJ, Ropella, GEP   +4 more
core   +2 more sources

Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients

Drug Design, Development and Therapy, 2021
Muhammad Nasir Kalam,1 Muhammad Fawad Rasool,2 Faleh Alqahtani,3 Imran Imran,4 Asim Ur Rehman,1 Naveed Ahmed1 1Department of Pharmacy, Quaid-i-Azam University, Islamabad, 45320, Pakistan; 2Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin ...
Kalam MN, Rasool MF, Alqahtani F, Imran I, Rehman AU, Ahmed N   +5 more
doaj  

Physiologically based pharmacokinetic and toxicokinetic modeling: A multidisciplinary approach to drug development and ecotoxicology [PDF]

Hospital Pharmacology
Introduction: Physiologically based pharmacokinetic (PBPK) modeling is a powerful tool in pharmaceutical research and drug development, offering accurate predictions of drug absorption, distribution, metabolism, and elimination (ADME).
Todorović Nemanja B., Ćoškov Aleksandra D., Andrić Nebojša Lj., Stanić Bojana Đ., Milijašević Boris Ž., Milošević Nataša P., Janković Slobodan M., Lalić-Popović Mladena N.   +7 more
doaj   +1 more source

Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 3 approved, 2 approved with reservations]

Gates Open Research, 2023
Physiologically based pharmacokinetic (PBPK) models represent computational technology to characterize drug behavior within the context of detailed human physiology.
Jolien Freriksen, Susan Cole, Joyce van der Heijden, Karen R Yeo, Trevor Johnson, Essam Kerwash, Marika de Hoop-Sommen, Rick Greupink, Janet Nooney, Saskia de Wildt, Ping Zhao   +10 more
doaj   +1 more source

Current trends in drug metabolism and pharmacokinetics. [PDF]

, 2019
Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion (ADME) processes of a drug. Understanding PK properties is essential for drug development and precision medication.
Abduljalil, Aghazadeh-Habashi, Aigrain, Aitman, Al Za'abi, Alegre, Alnaqeeb, Aspromonte, Babiskin, Baert, Bakke, Barnett, Bhattacharyya, Cang, Cannady, Cao, Cao, Capecchi, Chen, Chen, Chen, Chen, Chen, Chen, Chen, Cheng, Cheng, Crawford, Currie, De Lange, Dean, Deng, Di Paolo, Dietrich, Diliberto, Dluzen, Dowling, Dragin, Dreisbach, Duan, Edeogu, Edginton, El-Arabey, El-Kadi, EMA, Eum, Falany, Fang, FDA, Feng, Feng, Feng, Ferri, Fleming, Foti, Fox, Freedman, Frye, Fukami, Gaj, Gan, Gao, Gao, Gao, Gao, Gao, Ge, Genovese, Gingell, Gingell, Gong, Graham, Gufford, Guo, Guo, Guo, Guévin, Han, Harrison, Hartz, Hasegawa, He, He, He, He, He, Ho, Ho, Hou, Hsu, Hsueh, Hu, Hu, Hu, Huo, Hwang, Ito, Jacob, Jeong, Jeong, Jia, Jian, Jiang, Jiang, Jiang, Jiang, Jilek, Jilek, Johnson, Jorga, Jung, Kaivosaari, Kalthoff, Kaminsky, Kannan, Karibe, Kesisoglou, Kim, Kim, Knights, Kong, Kota, Kumar, Kurokawa, Lai, Lan, Lanchote, Lee, Lehouritis, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Li, Liang, Lin, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Lopes-Rodrigues, Lu, Lu, Lu, Löfgren, Mano, Marchitti, Margolskee, Martin, Matsson, Mattick, Mazerska, Mei, Mencia, Meng, Min, Mitra, Miyajima, Müller, Nair, Nakano, Nakano, Nakano, Nebert, Nguyen, Niederalt, Nieto Montesinos, Niu, Notenboom, Nozaki, Ohtsuki, Ono, Oostendorp, Pan, Pan, Papageorgiou, Papageorgiou, Park, Pea, Pedersen, Pelkonen, Pellegrino, Pettersson Bergstrand, Qi, Qin, Qiu, Qiu, Raaska, Rives, Riviere, Roberts, Robey, Rocha, Rose, Routy, Rowland, Ruwali, Saini, Satoh, Savage, Scheer, Scheer, Schlender, Schmitt, Schneider, Seitz, Showande, Shu, Shu, Shu, Shugarts, Siu, Song, Staudinger, Strong, Suarez-Sharp, Suh, Suiko, Sukkummee, Sun, Sun, Sutliff, Takeda, Tan, Tan, Tao, Tatsumi, Teorell, Tsai, Tsang, Tsuchiya, Tsume, Tu, Ulldemolins, van Waterschoot, von Richter, Vugmeyster, Vuppugalla, Wagner, Wagner, Wagner, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wang, Wassenaar, Watanabe, Wei, Wijayakumara, Wilkinson, Wong, Wu, Xia, Xie, Xie, Xu, Xu, Xu, Xu, Xu, Xue, Yamagata, Yamaguchi, Yan, Yang, Yang, Yang, Ye, Yellepeddi, Yi, Yi, Yigitaslan, Yim, Yin, Yoshida, Yoshida, Yoshimi, Yu, Yu, Yu, Yu, Yu, Yu, Yu, Zakeri-Milani, Zanger, Zeng, Zeng, Zhai, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhang, Zhao, Zhao, Zhao, Zhao, Zhou, Zhou, Zhou, Zhou, Zhou, Zhu, Zhu, Zhu, Zhuang, Zimmermann   +332 more
core   +1 more source

Development and Evaluation of Physiologically Based Pharmacokinetic Drug–Disease Models for Predicting Rifampicin Exposure in Tuberculosis and Cirrhosis Populations

Pharmaceutics, 2019
The physiologically based pharmacokinetic (PBPK) approach facilitates the construction of novel drug−disease models by allowing incorporation of relevant pathophysiological changes.
Muhammad F. Rasool, Sundus Khalid, Abdul Majeed, Hamid Saeed, Imran Imran, Mohamed Mohany, Salim S. Al-Rejaie, Faleh Alqahtani   +7 more
doaj   +1 more source